1.
Rev. esp. enferm. dig
; 109(10): 736-737, oct. 2017.
Artigo
em Espanhol
| IBECS
| ID: ibc-166833
RESUMO
No disponible
Assuntos
Humanos , Lactulose/uso terapêutico , Enema/instrumentação , Encefalopatia Hepática/diagnóstico , Encefalopatia Hepática/terapia , Fatores de Risco , Segurança do Paciente/normas , Enema/métodos , Enema , Fosforilcolina/uso terapêutico
2.
Rev Esp Enferm Dig
; 109(10): 736-737, 2017 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28929776
RESUMO
The administration of lactulose enemas instead of or in combination with oral lactulose is common practice in patients with hepatic encephalopathy. Lactulose is a non-absorbable disaccharide that is catabolized by the bacterial flora to short chain fatty acids (e.g., lactic acid and acetic acid) which lower the colonic pH. This pH favors the formation of non-absorbable NH4+ from NH3, trapping NH4+ in the colon and thus reducing plasma ammonia concentrations. Lactulose therapy is considered as a first-line treatment and can be administered both orally and rectally.